Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06115135 · ClinicalTrials.gov registry record · Phase 2
A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma
A Phase 2 study of Multiple Myeloma in Relapse and Multiple Myeloma, Refractory, sponsored by Oncotherapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
- 2
- Study locations
NCT06115135: Recruiting Phase 2 study of Multiple Myeloma in Relapse and Multiple Myeloma, Refractory, sponsored by Oncotherapeutics.
NCT06115135 is a Phase 2 study of Multiple Myeloma in Relapse and Multiple Myeloma, Refractory that is actively recruiting participants, run by Oncotherapeutics. The registered enrollment target is 39 participants, below the 48-participant average among 12 other Multiple Myeloma in Relapse trials with a reported enrollment target (19% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06115135, a Phase 2 study of Multiple Myeloma in Relapse and Multiple Myeloma, Refractory, is actively recruiting participants, sponsored by Oncotherapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
- 2
- Study locations
Study Summary
A phase 2 study of venetoclax in combination with isatuximab and dexamethasone for relapsed/refractory multiple myeloma patients with t(11;14)
Primary Outcome
Safety will be measured by counting the occurrence of adverse events throughout the study, graded via Common Terminology Criteria for Adverse Events (CTCAE) v 5.0 criteria
Conditions Studied
Interventions
- DRUG Venetoclax
Study Locations (2)
California
- Berenson Cancer Center - West Hollywood
Nebraska
- Nebraska Cancer Specialists - Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2024-06-20 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 2 |
What NCT06115135 shows while recruiting
NCT06115135 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 48-participant average among 12 other Multiple Myeloma in Relapse trials with a reported enrollment target (19% lower).
The record links to 2 conditions, with Multiple Myeloma in Relapse appearing as the primary indexed condition, and to 1 intervention - of which Venetoclax is the first listed.
NCT06115135 reports a single indexed study location in California, Nebraska.
Frequently Asked Questions
What is clinical trial NCT06115135 about?
NCT06115135 is a clinical study titled "A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma". A phase 2 study of venetoclax in combination with isatuximab and dexamethasone for relapsed/refractory multiple myeloma patients with t(11;14)
What is the current status of trial NCT06115135?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2024-06-20. Estimated completion is 2027-12-31.
What conditions does trial NCT06115135 study?
This clinical trial studies the following conditions: Multiple Myeloma in Relapse, Multiple Myeloma, Refractory.
What interventions are being tested in trial NCT06115135?
The interventions under investigation include: Venetoclax (DRUG).
Who is sponsoring clinical trial NCT06115135?
This trial is sponsored by Oncotherapeutics, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06115135 being conducted?
This trial has 2 study locations across California, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma in Relapse
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06115135's enrollment target sits among peer trials
39 5th of 12 higher than 8 of 12 other Multiple Myeloma in Relapse trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma in Relapse trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse
RECRUITING · Phase 2
-
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
RECRUITING · Phase 2
-
HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM
RECRUITING · Phase 2
-
Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 2
-
Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 2
-
TriPRIL CAR T Cells in Multiple Myeloma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI